Placebo Controlled, Dose Escalation Study to Evaluate Safety, Pharmacokinetics & Efficacy of SAP-001 in Gout Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John M Hill, MD
Accel Research Sites (Avail Clinical Research)
Principal Investigator - Melanie Fein
High Point Clinical Trials Center
Principal Investigator - Peter Winkle
Anaheim Clinical Trials, LLC
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Anaheim Clinical Trials, Llc
Anaheim, California, United States
- Avail - Accel Research Sites
DeLand, Florida, United States
- High Point Clinical Trials Center
High Point, North Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Sept 2018
- Primary completion
- 2 Jun 2019
- Completion
- 31 Oct 2019
- Last update posted
- 14 Oct 2021
- Registered enrollment
- 24
- Registry id
- NCT03857165
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.